| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/01/2004 | WO2004019874A3 Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
| 07/01/2004 | WO2004019762A3 Deflectable spacer for use as an interspinous process implant and method |
| 07/01/2004 | WO2004018058A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004017906A3 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 07/01/2004 | WO2004017892A3 Drug eluting coatings for medical implants |
| 07/01/2004 | WO2004016612A3 New purine derivatives |
| 07/01/2004 | WO2004016086B1 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents |
| 07/01/2004 | WO2004014357A3 Therapeutic use of aryl amino acid derivatives |
| 07/01/2004 | WO2004013093A3 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 07/01/2004 | WO2004010948A3 Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| 07/01/2004 | WO2004010894A3 Ophthalmologic irrigation solutions and method |
| 07/01/2004 | WO2004006900A3 Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases |
| 07/01/2004 | WO2004006865A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004005513A3 Methods for specifically inhibiting histone deacetylase-7 and 8 |
| 07/01/2004 | WO2004005323A3 Affinity small molecules for the epo receptor |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2004000802A3 Scaffolded maleimide clusters for multivalent peptide assembly |
| 07/01/2004 | WO2003106622A3 Methods for treatment of acute lymphocytic leukemia |
| 07/01/2004 | WO2003106385A3 Process for screening fungitoxic compounds |
| 07/01/2004 | WO2003104416A3 Spliceosome mediated rna trans-splicing in stem cells |
| 07/01/2004 | WO2003100435A3 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2) |
| 07/01/2004 | WO2003099844A3 Protease inhibitors |
| 07/01/2004 | WO2003096984A3 Drug therapy for celiac sprue |
| 07/01/2004 | WO2003093297A3 Protein kinase modulators and methods of use |
| 07/01/2004 | WO2003092616A3 Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| 07/01/2004 | WO2003092584A3 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| 07/01/2004 | WO2003090674A3 Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
| 07/01/2004 | WO2003086325A3 Cyanamides useful as reversible inhibitors of cysteine proteases |
| 07/01/2004 | WO2003082193A3 Suramin and derivatives thereof as topical microbicide and contraceptive |
| 07/01/2004 | WO2003072048A3 Symptomatic relief of gastrointestinal disorders |
| 07/01/2004 | WO2003057822A9 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/01/2004 | WO2003053445A8 Use of desoxypeganine for treating clinical depression |
| 07/01/2004 | WO2003053221A3 Methods using proton pump inhibitors |
| 07/01/2004 | WO2003051278A3 Nanoparticle delivery vehicle |
| 07/01/2004 | WO2003045369A9 Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses |
| 07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/01/2004 | WO2003017936A3 Use of dppiv inhibitors as diuretic and anti-hypertensive agents |
| 07/01/2004 | WO2002100341A3 Compounds for the treatment of metabolic disorders |
| 07/01/2004 | WO2002099083A3 Gfats as modifiers of the p53 pathway and methods of use |
| 07/01/2004 | WO1998008480A3 Method of using tetracycline compounds for inhibition of nitric oxide production |
| 07/01/2004 | US20040127884 Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
| 07/01/2004 | US20040127713 relaxing action of tracheal smooth muscles, inhibition of airway hypersensitivity and inhibition of infiltration of inflammatory cells into the airway; useful as antiasthmatic drugs |
| 07/01/2004 | US20040127712 Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors |
| 07/01/2004 | US20040127709 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| 07/01/2004 | US20040127708 antiviral activities; aids treatment |
| 07/01/2004 | US20040127707 Novel phthalazinones |
| 07/01/2004 | US20040127705 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action |
| 07/01/2004 | US20040127702 Novel crystal form |
| 07/01/2004 | US20040127699 Cosmetics, drugs |
| 07/01/2004 | US20040127696 Growth differentiation factor-7 |
| 07/01/2004 | US20040127686 Signal transduction regulator binding protein for identifying modulators for prevention and treatment of cardiomyopic hypertrophy, heart failure and diabetes; drug screening |
| 07/01/2004 | US20040127618 Tough polymers |
| 07/01/2004 | US20040127578 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
| 07/01/2004 | US20040127577 Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| 07/01/2004 | US20040127576 Estrogen receptor modulators |
| 07/01/2004 | US20040127575 administering an effective amount of a compound capable of inhibiting TGF- beta signaling through a TGF- beta receptor |
| 07/01/2004 | US20040127574 Aminoethanol derivatives |
| 07/01/2004 | US20040127573 Methods for increasing bone density |
| 07/01/2004 | US20040127572 the prevention or amelioration of sleep-related breathing disorders such as sleep apnea |
| 07/01/2004 | US20040127569 involving an overproduction of nitric oxide (NO) by inducible nitric oxide synthase (iNOS) by administering to the subject an anti-inflammatory effective amount of an inducible nitric oxide synthase selective inhibitor |
| 07/01/2004 | US20040127568 Therapeutic use of D-methionine to reduce the toxicity of radiation |
| 07/01/2004 | US20040127567 cystic fibrosis; or a chronic inflammatory disorder, e.g., ulcerative colitis, Crohn's disease, chronic pancreatitis, asthma, rheumatoid arthritis or chronic gastritis; abrogated fetal lung surfactant biosynthesis |
| 07/01/2004 | US20040127566 all-trans retinoic acid (inter alia, liposomal all-trans retinoic acid) of at least about 10 mg at least about every other day |
| 07/01/2004 | US20040127565 Quarternary ammonium compounds |
| 07/01/2004 | US20040127563 composition, comprising: unsaturated vegetable oil ester; adipate; and vegetable oil polyols stimulates bone growth; glyceride and water within the mammal is converted into glycerol, fatty acid, and protons |
| 07/01/2004 | US20040127562 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 07/01/2004 | US20040127561 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings, method therefor |
| 07/01/2004 | US20040127559 with acetic acid inactivate the infectability of infectious proteins such as prions under relatively mild conditions |
| 07/01/2004 | US20040127558 Sodium dodecyl sulfate compositions for inactivating prions |
| 07/01/2004 | US20040127557 liquid preparations of oxaliplatin, ready to be administered parenterally by infusion; concentration of at least 7 mg/ml; solvent is one hydroxylated derivative chosen from 1,2-propanediol, glycerol, maltitol, sucrose and inositol |
| 07/01/2004 | US20040127556 Administering limonoid comprising toosendanin and/or azadirachtin plant extracts; aging resistance; muslce relaxation by inhibiting acetylcholine release at neuromuscular junctions |
| 07/01/2004 | US20040127555 bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis |
| 07/01/2004 | US20040127552 Benzoaxathiepin derivatives and their use as medicines |
| 07/01/2004 | US20040127551 increaqsing bioavailability of oral dosage of taxanes with a carrier comprising vitamin E TPGS, a co-solubilizer comprising ethanol in an amount of at least about 5% by weight of the composition, and propylene glycol, and a stabilizer |
| 07/01/2004 | US20040127550 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 07/01/2004 | US20040127549 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases |
| 07/01/2004 | US20040127547 Prodigiosin composition for the treatment of rheumatic arthritis |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127541 Bicifadine formulation |
| 07/01/2004 | US20040127539 Antiangiogenic combination therapy for the treatment of cancer |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127536 Indazole Derivatives |
| 07/01/2004 | US20040127533 Sulfonamide derivatives |
| 07/01/2004 | US20040127532 Method for synthesizing leflunomide |
| 07/01/2004 | US20040127531 backing sheet that is flexibly conformable to the area of skin coated on the proximal surface of thereof with an adhesive and an active agent comprising valdecoxib or a prodrug thereof or a salt thereof |
| 07/01/2004 | US20040127529 Remedies for skin ulcer |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127527 Large conductance calcium-activated k channel opener |
| 07/01/2004 | US20040127526 elevating the HDL concentration and treating atherosclerosis and related coronary heart disease and dyslipoproteinemias |
| 07/01/2004 | US20040127523 Methods of treating cancer with HDAC inhibitors |
| 07/01/2004 | US20040127522 histone deacetylase inhibitors administered in a safe, daily dosing regimen to have high oral bioavailability |
| 07/01/2004 | US20040127521 to be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs |
| 07/01/2004 | US20040127519 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
| 07/01/2004 | US20040127517 For therapy of treat atherosclerosis, autoimmune diseases, multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases, idiopathic pulmonary fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout |
| 07/01/2004 | US20040127516 Substituted dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-amines and the use of the same as analgesics |
| 07/01/2004 | US20040127513 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
| 07/01/2004 | US20040127512 Administering methscopolamine bromide for therapy of symptoms of non-constipated irritable bowel syndrome (IBS) and diarrhea-predominant IBS |
| 07/01/2004 | US20040127511 Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |